Sakar Healthcare Limited (SAKAR)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 1 August 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹885.25 ↑ 141.87% (1Y)

🎯 Key Takeaways

Sakar Healthcare Limited is transitioning from a diversified pharmaceutical player to a focused, regulatory-driven oncology CDMO with strong international expansion. The company is leveraging its oncology product pipeline and EU marketing authorisations to drive high-margin growth, marking a strategic shift toward scalable, export-oriented operations in regulated markets.
Revenue grew 1.5% QoQ to ₹43 in Q3FY25.
⚠️ Execution risks in international markets, particularly in scaling operations across new geographies with regulatory complexity, are explicitly highlig

Market Cap

₹1,550

P/E Ratio

102.3

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About SAKAR 📊 Interactive Charts

📖 The Story

Sakar Healthcare Limited is transitioning from a diversified pharmaceutical player to a focused, regulatory-driven oncology CDMO with strong international expansion. The company is leveraging its oncology product pipeline and EU marketing authorisations to drive high-margin growth, marking a strategic shift toward scalable, export-oriented operations in regulated markets.

📰 What's Happening

In Q1FY27, Sakar Healthcare reported consolidated revenue of ₹7,297 crores, up 38% YoY, driven by oncology product launches and export growth, with PAT surging 120% to ₹1,028 crores and EBITDA rising 67% to ₹2,125 crores. The company executed 65 new oncology contracts and secured 16 EU Marketing Authorisations, supporting its transition to an integrated oncology-focused CDMO model. Management highlighted that converting regulatory approvals into commercial launches will enhance capacity utilization and operating leverage, targeting sustained profitability through its oncology platform expansion.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	41	39	34	37	43	41	43	43
Operating Profit	10	11	10	9	12	11	12	12
OPM %	19.1%	23.2%	27.5%	24.2%	25.5%	26.0%	26.9%	27.1%
Net Profit	4	3	4	2	3	2	5	5
EPS	₹2.04	₹1.46	₹1.68	₹0.98	₹1.46	₹1.10	₹2.17	₹2.08

The company has demonstrated consistent top-line and margin expansion over recent quarters, with Q1FY27 marking the strongest profitability metrics to date — gross margin improved to 53% and EBITDA margin to 29%, up from 24% and 19.1% respectively in prior periods. This improvement aligns with management's stated focus on cost discipline and operational leverage, as evidenced by PAT growth outpacing revenue growth (120% vs 38% YoY), reflecting successful scaling of high-margin oncology offerings.

🔮 Management Outlook & What's Next

Management expects to convert regulatory approvals into commercial launches and supply agreements to improve capacity utilization and sustain earnings momentum, positioning the business for scalable growth in global oncology markets. The transition to an integrated, regulatory-driven CDMO model is central to their strategy, with emphasis on pipeline development and international market penetration as key growth drivers.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

Execution risks in international markets, particularly in scaling operations across new geographies with regulatory complexity, are explicitly highlighted by management. Additionally, the company's strategic shift to oncology CDMO model introduces concentration risk, as future growth depends heavily on successful commercialization of oncology products and maintaining regulatory momentum.

📋 Recent Filings

🧠 Analyst's Read

Sakar Healthcare is executing a clear strategic pivot toward high-margin oncology exports with strong regulatory progress, resulting in accelerating profitability. Investors should monitor the pace of commercial launches from new authorisations and the sustainability of margin expansion as the company scales its CDMO operations globally.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on SAKAR

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-01.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SAKAR files new disclosures

Track SAKAR filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SAKAR — Free

Free account · 2 AI queries/day